Objectives: This study aimed to determine whether expectations of treatment outcomes in women participating in a drug and behavioral treatment trial for urge urinary incontinence are related to patient factors, demographics, health-related locus of control, and treatment outcomes.
O utcomes from the treatment of urinary incontinence (UI) in women are assessed with a wide range of measures, including both bladder diary assessment of UI frequency and severity and patient-reported outcomes (PROs). Validated PROs are increasingly being used in UI treatment trials and include perception of UI severity, bother, and impact, as well as both UIspecific and general health-related quality of life (QoL). There has been little investigation on the impact of health beliefs, expectations, and psychological factors on diary and PRO UI treatment outcomes. A personality factor that reasonably could have a major impact on patient expectations and eventual treatment outcome is health locus of control (HLC). Health locus of control is the patients' perception of whether their general or condition-specific health and their power to affect their health comes primarily from within themselves, is primarily subject to chance, or primarily under the control of others. 1 The objectives of this study were to determine (1) whether, in a sample of women enrolled in a clinical trial for treatment of urgency-predominant UI, expectations of treatment outcome were related to patient demographic factors, UI severity, comorbid conditions, and HLC; and (2) whether expectations of treatment outcome and HLC were significantly associated with eventual patient-reported treatment outcomes. Our study was prompted by the hypothesis that patients' health beliefs, expectations of treatment, and other psychological factors may be important determinants of UI treatment outcomes as measured by PROs.
METHODS
The Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study was conducted at nine university-based clinical centers of the National Institutes of HealthYsponsored Urinary Incontinence Treatment Network, supported by a data-coordinating center. The institutional review boards of the participating centers approved the study, and all participants provided written informed consent.
The methods and primary results of this trial have been published elsewhere. 2 In brief, the BE-DRI study was a 2-stage randomized blinded clinical trial in which women with urgency or urgency-predominant UI were randomized to receive openlabel drug therapy alone (tolterodine tartrate extended-release 4 mg daily) or drug therapy combined with behavioral training (instruction in performance of pelvic floor muscle exercises, individualized fluid management and strategies to decrease urgency, suppress bladder contractions, prevent UI, and decrease frequent voiding). Women were eligible if they had urgency-predominant UI present for at least 3 months, recorded at least 7 UI episodes on a 7-day bladder diary, had no confounding comorbid conditions, and were not currently using medications that could affect UI. A total of 307 women were enrolled and randomized, and 237 completed the study. Both groups completed daily bladder diaries during stage 1 (active therapy, 10 weeks). At the end of stage 1, both drug and behavioral training sessions were discontinued, and subjects receiving behavioral therapy were asked to continue their behavioral program for the duration of the study. During the next 6 months (stage 2), subjects who requested to restart drug were allowed to resume the drug at no cost. Primary and secondary outcomes were assessed at the end of stage 2 (8 months after study start; Fig. 1 ).
ORIGINAL ARTICLE
The primary outcome of this analysis was assessed at trial end (8 months after study start) using the Patient Global Impression of Improvement (PGI-I) scale (''Overall, do you feel that you are much better, better, about the same, worse, or much worse?''). 3 In addition, at baseline, patients completed 2 measures of symptom distress (Urogenital Distress Inventory [UDI] and the Overactive Bladder Questionnaire [OAB-q]), a measure of UI-specific impact (Incontinence Impact Questionnaire [IIQ]), and 2 measures of QoL (the OAB-q health-related QoL scale and the 12-item Short-Form Health Survey ).
4Y6
In addition to routine study measures, patients completed an expectations questionnaire at baseline. Because little is known about patients' expectations of the drug treatment, we designed the questionnaire to capture several domains of improvement ( Table 1) including degree of symptom change (''Get very much better / a little better / stay about the same as now / a little worse / a lot worse''), time of onset of symptom change (''About a week / about 4 weeks / about 8 weeks / about 10 weeks / no opinion''), and duration of symptom change (''One month / 6 months / 1 year / for the rest of my life'').
Locus of control was assessed at baseline using the Medical Health Locus of Control (MHLC) for condition-specific health (Form C), using UI as the condition. 1 The MHLC Form C consists of 18 statements (items), each beginning with the stem, ''Each item below is a belief statement about your health condition (here, urinary leakage) with which you may agree or disagree.'' Items ''If you are assigned to have both drug and behavioral therapy, do you expect that the improvement in your bladder condition will be mostly due to the effect of the drug, of the behavioral therapy, due to equal effects of drug and behavioral therapy, or no opinion about whether due to drug or behavioral therapy?'' Time until improvement ''How long do you think it will take the treatment you receive to begin to improve your bladder condition, about 1 wk, 4 wk, 8 wk, 10 wk, no opinion?'' Duration of improvement ''How long do you believe that the improvement in your bladder condition will last after you finish this study, 1 mo, 6 mo, 1 y, for the rest of life?'' are scored on a 6-point Likert scale (from 1 ''strongly disagree'' to 6 ''strongly agree''), and are grouped into 4 control subscales: internal locus of control, chance, doctors, and other people ( Table 2 ). Scores are reported as mean for each subscale; there is no summary score. The MHLC questionnaire is included as an Appendix to this article. Ten weeks after enrollment (after 8 weeks of active treatment), participants reported their treatment success using the PGI-I scale 3 : ''Overall, compared to before treatment, my bladder condition is now I Very much better / A little better / About the same / A little worse / Very much worse.'' The PGI-I scale was completed again at study end, after a further 8 months without active treatment.
We used cross-classification and W 2 analysis to investigate factors associated with patient expectations and to determine whether baseline patient expectations predicted the patientreported PGI-I at 10 weeks and 8 months after the start of the study. Analyses were carried out using SAS statistical software, version 9.1 (SAS Institute, Inc, Cary, NC).
RESULTS
In the parent BE-DRI study, we screened 4043 women, consented 561, and randomly assigned 307.
2 Development and face validation in a convenience clinical sample of urge incontinent women delayed introduction of the expectations questionnaire until after initial enrollment in the parent study had begun, so that only 173 (56%) of the total 307 women were consecutively enrolled for the current analyses. All 173 completed the expectations questionnaire at baseline. Of these, 137 (79%) had PGI-I outcome data at study end.
At baseline, women had high expectations of UI-specific outcomes (Table 3 ). All women expected that their UI would improve; 66% expected UI to get ''very much better'' and 34% expected their UI would ''get a little better or stay the same.'' Fifty-five percent expected to experience improvement by 1 month, and 66% expected that improvement would last for the rest of their lives. There were no significant associations between baseline degree of expected improvement and either expected time to improvement or expected duration of improvement (data not shown).
At baseline, race/ethnicity and education were the only demographic or clinical patient characteristics associated with high expectation of improvement (''get very much better'') ( Table 4) . Compared with the other groups, non-Hispanic black women had lower expectations of improvement. High expectations were also associated with greater baseline UI severity as measured by Medical, Epidemiological and Social Aspects of Aging urge index and IIQ, but not daily UI frequency on bladder diary. Similarly, subjects with high expectations reported greater UI impact on QoL as measured by the OAB-q health-related QoL scale and the SF-12. However, there was no association between expectations and UI-related bother on the UDI.
For the MHLC at baseline, the interitem reliability of the standardized scores for each subscale (Cronbach > = 0.58Y0.86) was similar to that previously reported for the condition-specific MHLC (> = 0.71Y0.87), suggesting that this adaptation of the MHLC Form C functioned well in this group of patients. 7 The ''doctors'' subscale had the lowest interitem reliability, also consistent with previous literature. 7 Women participating in this substudy scored highest for ''doctors'' (mean [SD], 13.2 [3.2] ; median, 13/18 possible points) and ''internal'' control (19.1 [6.5] ; median, 20/36 possible points) and lower for ''others'' (8.6 [3.9] ; median, 8/18 possible points) and ''chance'' (12.7 [6.7] ; median, 11/36 possible points). Urinary incontinenceYspecific locus of control was not significantly related to expectations of treatment outcome. Table 5 details PROs as assessed by the PGI-I at 10 weeks and at trial end. The association between baseline degree of expected improvement and PGI-I was not statistically significant at either 10 weeks or trial end. Similarly, there was no association between MHLC scale scores and PGI-I at 10 weeks or trial end (data not shown). We estimated the power to detect the results reported in Table 5 as statistically significant at the 5% significance level. The sample of 137 women provides 31% power to detect the observed association at 10 weeks and 16% power for the observed association at trial end. Sample sizes of 456 and 984 are needed to have 80% power for the observed associations at 10 weeks and trial end, respectively.
DISCUSSION
In this sample of women with urgency-predominant UI participating in a drug and behavioral treatment trial, treatment outcome as assessed by the PGI-I was not predicted either by baseline degree of expected improvement or by subjects' UIspecific health locus of control. In addition, we found that the MHLC seems to function adequately when used in women with urgency UI. It is not possible to directly compare our results to those of other researchers because there are no similar published studies among women with urgency UI. Our results contrast with other prior studies examining the relationship between expectations and treatment outcomes in other health conditions. 7 The effect size of patient expectations on outcomes of laparoscopic surgery and of treatments for low back pain, myocardial infarction, obesity, and psychiatric conditions has been demonstrated to be medium to large. 7 However, our findings are similar to treatment trials in 2 patient-reported, symptom-defined conditions, pain, and chronic fatigue. There was no consistent relationship between expectations and health related locus of control in a trial of acupuncture 8 and no correlation between locus of control and PROs in a randomized treatment trial for fatigue in primary care patients. 9 Flood et al 10 postulated 5 mechanisms by which expectations may affect outcomes: triggering a physiologic response, improving motivation to achieve better outcomes, changing understanding of the disease, psychological conditioning to observe or ignore certain symptoms, and acting together with anxiety to heighten or reduce symptoms. Thus, knowledge of the impact of expectations could be important for clinicians and researchers; for example, it has been suggested that patient support and education can be tailored to explicitly address and modify expectations with the aim of improving outcomes.
Outcomes from treatment of UI in women have been assessed with a wide range of measures, ranging from quantification of UI severity to PROs of UI severity, bother, and impact, and UI-specific and general health-related QoL. With the increased use of validated PRO measures in UI treatment trials, it is extremely important to understand determinants of these PROs. Although UI frequency and patient report of the impact of UI generally parallel one another at baseline (ie, patients with greater UI frequency have worse UI-specific QoL) and after treatment (decrease in UI frequency is associated with improved UIspecific QoL), there is significant interindividual variation, and overall correlations are accordingly moderate to small. The demographic factor age has variable effects on PRO and placebo response rates. 11, 12 Our study was prompted by the hypothesis that patients' health beliefs, expectations of treatment, and other psychological factors may be important determinants of UI treatment outcomes as measured by PROs. Such factors are known to influence helpseeking for UI 13Y15 and to affect UI-specific QoL. For example, in women, UI is associated with a lower sense of mastery and competence, and mastery is significantly associated with UIspecific QoL. 16 Explanatory style, the habitual manner in which individuals use specific types of causal explanations for bad events or illness, is related to urgency UI-specific QoL in older persons. 17 There has been little investigation on the impact of health beliefs, expectations, and psychological factors on UI treatment outcomes except regarding anti-UI surgery 17, 18 and a small study of behavioral treatment. 19 One relevant study regarding pharmacological treatment of urgency UI demonstrated that patients' belief that they had been randomized to active drug treatment in a randomized UI drug trial was significantly associated with favorable bladder diary and QoL outcomes 20 but did not measure patient expectations and could not be compared to our data.
Our study is limited by its sample size with associated low power and by its generalizability but is strengthened by the inclusion of well-characterized patients from several centers. It is also possible that our expectations questionnaire was not sensitive enough to adequately discern expectations of degree, onset, or duration of improvement after treatment. Further, dichotomization of improvement into high versus low expectation may have made it more difficult to demonstrate a significant correlation between patient expectation and treatment results. Our study is also limited by the fact that all women were enrolled in a treatment trial and specifically seeking pharmacologic treatment of UI, leading to the very high expectations at baseline. Participants were unlikely to be naive to prior behavioral and/or drug treatment, which could have mitigated expectations. It is possible that, if our sample had been more broadly representative of women with UI and with more variable baseline expectations, an association between expectation and outcome would have been evident. Furthermore, attrition bias could be masking an association if women who had lower (or higher) expectation and higher (or lower) perceived improvement were less likely to complete the follow-up assessment.
Another personality factor that could reasonably have an important impact on eventual treatment ''success'' as measured by PROs is a patient's baseline degree of optimism/pessimism. Along with further assessment of patient expectation and HLC, this could be a focus of future research.
In conclusion, this analysis suggests that women seeking treatment of urge-predominant UI in a randomized trial have very high expectations for treatment, which were not associated with outcomes. Further studies are needed to assess whether expectations of treatment in clinical settings may relate to PROs and diary outcomes. Most things that affect my urine leakage happen to me by chance. D5.
STEERING COMMITTEE
Whenever my urine leakage worsens, I should consult a medically trained professional. D6.
I am directly responsible for my urine leakage getting better or worse. D7.
Other people play a big role in whether my urine leakage improves, stays the same, or gets worse. D8.
Whatever goes wrong with my urine leakage is my own fault. D9.
Luck plays a big part in determining how my urine leakage improves. D10.
In order for my urine leakage to improve, it is up to other people to see that the right things happen. D11.
Whatever improvement occurs with my urine leakage is largely a matter of good fortune. D12.
The main thing that affects my urine leakage is what I myself do. D13.
I deserve the credit when my urine leakage improves and the blame when it gets worse. D14.
Following doctor's orders to the letter is the best way to keep my urine leakage from getting any worse. D15.
If my urine leakage worsens, it is a matter of fate. D16.
If I am lucky, my urine leakage will get better. D17.
If my urine leakage takes a turn for the worse, it is because I have not been taking proper care of myself. D18.
The type of help I receive from other people determines how soon my urine leakage improves.
